Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin for Major Depressive Disorder in Adults With Cancer
NCT05947383Phase 2Active, not recruiting
- Sponsor
- Sunstone Therapies
- Start
- Oct 2023
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Psilocybin with Placebo (2 arms). Primary endpoint: Montgomery-Asberg Depression Rating Scale at 8 weeks. Started Oct 2023; status: active, not recruiting.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05947383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947383.